Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 14/20 | 0.37 |
| ▸ | SLC2A3 | P11169 | 14/20 | 0.37 |
| ▸ | SLC2A4 | P14672 | 14/20 | 0.37 |
| ▸ | SLC2A2 | P11168 | 6/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10118291 | 0.93 | SLC2A1 (0.36) | SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL10118300 | 0.93 | SLC2A1 (0.36) | SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL782240 | 0.87 | SLC2A1 (0.38) | SLC2A1SLC2A3SLC2A4SLC2A2ELANE | |
| SCHEMBL10118297 | 0.86 | OPRL1 (0.36) | SLC2A1SLC2A3SLC2A4SLC2A2ELANE | |
| SCHEMBL10136318 | 0.82 | SLC2A1 (0.35) | SLC2A1SLC2A3SLC2A4SLC2A2NTRK1 | |
| SCHEMBL563502 | 0.81 | KMT2A (0.36) | SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL12956899 | 0.81 | PKM (0.42) | SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL30845280 | 0.81 | KMT2A (0.36) | SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL10140212 | 0.81 | CARM1 (0.38) | SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL12158541 | 0.81 | CARM1 (0.38) | SLC2A1SLC2A3SLC2A4SLC2A2ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582688-B1 | ANTHRANILIC ACID DIAMIDE DERIVATIVES | BAYER IP GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-8791139-B2 | Anthranilic diamide derivatives | BAYER CROPSCIENCE AG (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8791139-B2 | Anthranilic diamide derivatives | BAYER CROPSCIENCE AG (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20120015980-A1 | ANTHRANILIC DIAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2012-01-19 | — | — | US | disclosed |
| US-20120015980-A1 | ANTHRANILIC DIAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015980-A1 | ANTHRANILIC DIAMIDE DERIVATIVES | DDT, QDPR, ANTXR2 | SLC2A1 3127/4885SLC2A3 3314/4885SLC2A4 3392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.